The single RBP-Jκ site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection

Journal of Virology

Volumn 85, Issue 13, 2011, Pages 6148-6161

  Lu, Jie ^a   Verma, Subhash C ^b   Cai, Qiliang ^a   Robertson, Erle S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; LATENCY ASSOCIATED NUCLEAR ANTIGEN; RTA PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; IMMEDIATE EARLY PROTEIN; LATENCY-ASSOCIATED NUCLEAR ANTIGEN; NUCLEAR PROTEIN; RBPJ PROTEIN, HUMAN; RTA PROTEIN, HUMAN HERPESVIRUS 8; TRANSACTIVATOR PROTEIN; VIRUS ANTIGEN;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BINDING SITE; CONTROLLED STUDY; EMBRYO; GENE DELETION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; VIRUS LATENCY; VIRUS RECOMBINANT; VIRUS REPLICATION; CELL LINE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC RECOMBINATION; GENETICS; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

BACTERIA (MICROORGANISMS); HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

ANTIGENS, VIRAL; BINDING SITES; CELL LINE; CHROMOSOMES, ARTIFICIAL, BACTERIAL; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; LEUKOCYTES, MONONUCLEAR; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RECOMBINATION, GENETIC; TRANS-ACTIVATORS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 80052047643     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02608-10     Document Type: Article

References (90)

1. An, F. Q., et al. 2005. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J. Biol. Chem. 280:3862-3874.
2. Barcy, S., et al. 2008. Gamma delta+ T cells involvement in viral immune control of chronic human herpesvirus 8 infection. J. Immunol. 180:3417- 3425.
3. Boivin, G., A. Gaudreau, and J. P. Routy. 2000. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 14:1907-1910.
4. Borggrefe, T., and F. Oswald. 2009. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell. Mol. Life Sci. 66:1631-1646.
5. Brown, E. E., et al. 2006. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 107:2282-2290.
6. Bu, W., et al. 2008. Identification of direct transcriptional targets of the Kaposi's sarcoma-associated herpesvirus Rta lytic switch protein by conditional nuclear localization. J. Virol. 82:10709-10723.
7. Bubman, D., I. Guasparri, and E. Cesarman. 2007. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26:4979-4986.
8. Cai, Q., et al. 2006. Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: latency control under low oxygen conditions. J. Virol. 80:7965-7975.
9. Cai, Q., M. Murakami, H. Si, and E. S. Robertson. 2007. A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1α in normoxia. J. Virol. 81:10413-10423.
10. Cai, Q., S. C. Verma, J. Y. Choi, M. Ma, and E. S. Robertson. 2010. Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency. J. Virol. 84: 11134-11144.
11. Cai, Q. L., J. S. Knight, S. C. Verma, P. Zald, and E. S. Robertson. 2006. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2:e116.
12. Cannon, J. S., et al. 2000. A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J. Virol. 74:10187-10193.
13. Cesarman, E., et al. 1995. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86:2708-2714.
14. Chang, H., et al. 2009. Non-human primate model of Kaposi's sarcomaassociated herpesvirus infection. PLoS Pathog. 5:e1000606.
15. Chang, Y., et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
16. Di Bartolo, D. L., et al. 2008. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 111: 4731-4740.
17. Fakhari, F. D., and D. P. Dittmer. 2002. Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J. Virol. 76:6213-6223.
18. Fortini, M. E. 2009. Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell 16:633-647.
19. Fujimuro, M., and S. D. Hayward. 2003. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3β. J. Virol. 77:8019-8030.
20. Fujimuro, M., J. Liu, J. Zhu, H. Yokosawa, and S. D. Hayward. 2005. Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. J. Virol. 79:10429-10441.
21. Fujimuro, M., et al. 2003. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. 9:300-306.
22. Ganem, D. 1997. KSHV and Kaposi's sarcoma: the end of the beginning? Cell 91:157-160.
23. Garber, A. C., M. A. Shu, J. Hu, and R. Renne. 2001. DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J. Virol. 75:7882-7892.
24. Godfrey, A., J. Anderson, A. Papanastasiou, Y. Takeuchi, and C. Boshoff. 2005. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105:2510-2518.
25. Groves, A. K., M. A. Cotter, C. Subramanian, and E. S. Robertson. 2001. The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters. J. Virol. 75:9446-9457.
26. Grundhoff, A., and D. Ganem. 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 113:124-136.
27. Guttman-Yassky, E., et al. 2007. Relationship between human herpesvirus 8 loads and disease stage in classic Kaposi sarcoma patients. Diagn. Microbiol. Infect. Dis. 57:387-392.
28. Hagen, T. 2009. Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3β. J. Virol. 83:6312- 6317.
29. Halder, S., et al. 2009. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4:e7214.
30. + T cell counts in antiretroviral-suppressed HIV-infected patients. PLoS One 4:e5277.
31. Jenner, R. G., M. M. Alba, C. Boshoff, and P. Kellam. 2001. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J. Virol. 75:891-902.
32. Kato-Noah, T., et al. 2007. Overexpression of the Kaposi's sarcoma-associated herpesvirus transactivator K-Rta can complement a K-bZIP deletion BACmid and yields an enhanced growth phenotype. J. Virol. 81:13519- 13532.
33. Kedes, D. H., M. Lagunoff, R. Renne, and D. Ganem. 1997. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J. Clin. Invest. 100:2606-2610.
34. Kerur, N., et al. 2010. Characterization of entry and infection of monocytic THP-1 cells by Kaposi's sarcoma associated herpesvirus (KSHV): role of heparan sulfate, DC-SIGN, integrins and signaling. Virology 406:103-116.
35. Knight, J. S., M. A. Cotter II, and E. S. Robertson. 2001. The latencyassociated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J. Biol. Chem. 276: 22971-22978.
36. Krithivas, A., D. B. Young, G. Liao, D. Greene, and S. D. Hayward. 2000. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J. Virol. 74:9637-9645.
37. Lan, K., D. A. Kuppers, and E. S. Robertson. 2005. Kaposi's sarcomaassociated herpesvirus reactivation is regulated by interaction of latencyassociated nuclear antigen with recombination signal sequence-binding protein Jκ, the major downstream effector of the Notch signaling pathway. J. Virol. 79:3468-3478.
38. Lan, K., D. A. Kuppers, S. C. Verma, and E. S. Robertson. 2004. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virusmediated control of latency. J. Virol. 78:6585-6594.
39. Lan, K., et al. 2005. Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J. Virol. 79:7453-7465.
40. Liang, Y., J. Chang, S. J. Lynch, D. M. Lukac, and D. Ganem. 2002. The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jκ (CSL), the target of the Notch signaling pathway. Genes Dev. 16:1977-1989.
41. Liang, Y., and D. Ganem. 2003. Lytic but not latent infection by Kaposi's sarcoma-associated herpesvirus requires host CSL protein, the mediator of Notch signaling. Proc. Natl. Acad. Sci. U. S. A. 100:8490-8495.
42. Liang, Y., and D. Ganem. 2004. RBP-J (CSL) is essential for activation of the K14/vGPCR promoter of Kaposi's sarcoma-associated herpesvirus by the lytic switch protein RTA. J. Virol. 78:6818-6826.
43. Lim, C., H. Sohn, Y. Gwack, and J. Choe. 2000. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. J. Gen. Virol. 81:2645-2652.
44. Liu, J., H. J. Martin, G. Liao, and S. D. Hayward. 2007. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J. Virol. 81:10451-10459.
45. Liu, P., N. A. Jenkins, and N. G. Copeland. 2003. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13:476-484.
46. Lu, F., L. Day, S. J. Gao, and P. M. Lieberman. 2006. Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcomaassociated herpesvirus lytic transcription. J. Virol. 80:5273-5282.
47. Lu, F., et al. 2003. Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J. Virol. 77:11425-11435.
48. Lu, J., et al. 2011. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 410:64-75.
49. Lu, J., et al. 2009. Latency-associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus (KSHV) upregulates survivin expression in KSHVassociated B-lymphoma cells and contributes to their proliferation. J. Virol. 83:7129-7141.
50. Lukac, D. M., R. Renne, J. R. Kirshner, and D. Ganem. 1998. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252:304-312.
51. Memar, O. M., P. L. Rady, and S. K. Tyring. 1995. Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions. J. Mol. Med. 73:603-609.
52. Mocarski, E. S., Jr. 1997. Propagating Kaposi's sarcoma-associated herpesvirus. N. Engl. J. Med. 336:214-215.
53. Moore, P. S., et al. 1996. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 10:175-180.
54. Murakami, Y., et al. 2006. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx. J. Biol. Chem. 281:28113-28121.
55. Myoung, J., and D. Ganem. 2011. Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology 413:1-11.
56. Nakamura, H., et al. 2003. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J. Virol. 77:4205-4220.
57. Neipel, F., and B. Fleckenstein. 1999. The role of HHV-8 in Kaposi's sarcoma. Semin. Cancer Biol. 9:151-164.
58. Ottinger, M., et al. 2006. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4-and BRD2/RING3-induced G1 cell cycle arrest. J. Virol. 80:10772-10786.
59. Paulose-Murphy, M., et al. 2001. Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J. Virol. 75:4843-4853.
60. Persson, L. M., and A. C. Wilson. 2010. Wide-scale use of Notch signaling factor CSL/RBP-Jκ in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes. J. Virol. 84:1334-1347.
61. Polstra, A. M., J. Goudsmit, and M. Cornelissen. 2003. Latent and lytic HHV-8 mRNA expression in PBMCs and Kaposi's sarcoma skin biopsies of AIDS Kaposi's sarcoma patients. J. Med. Virol. 70:624-627.
62. Rainbow, L., et al. 1997. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J. Virol. 71:5915-5921.
63. Rappocciolo, G., et al. 2008. Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J. Virol. 82:4793-4806.
64. Renne, R., et al. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342-346.
65. Rossetto, C., I. Yamboliev, and G. S. Pari. 2009. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 K-bZIP modulates latency-associated nuclear protein-mediated suppression of lytic origin-dependent DNA synthesis. J. Virol. 83:8492-8501.
66. Russo, J. J., et al. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U. S. A. 93:14862-14867.
67. Said, W., et al. 1996. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood 87:4937-4943.
68. Sakakibara, S., et al. 2004. Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J. Virol. 78:7299-7310.
69. Sarid, R., O. Flore, R. A. Bohenzky, Y. Chang, and P. S. Moore. 1998. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J. Virol. 72:1005-1012.
70. Schulz, T. F., and P. S. Moore. 1999. Kaposi's sarcoma-associated herpesvirus: a new human tumor virus, but how? Trends Microbiol. 7:196-200.
71. Schwam, D. R., R. L. Luciano, S. S. Mahajan, L. Wong, and A. C. Wilson. 2000. Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. J. Virol. 74:8532-8540.
72. Shamay, M., A. Krithivas, J. Zhang, and S. D. Hayward. 2006. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc. Natl. Acad. Sci. U. S. A. 103:14554-14559.
73. Si, H., and E. S. Robertson. 2006. Kaposi's sarcoma-associated herpesvirusencoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol. 80:697-709.
74. Soulier, J., et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
75. Spadavecchia, S., O. Gonzalez-Lopez, K. D. Carroll, D. Palmeri, and D. M. Lukac. 2010. Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J. Virol. 84:10488-10500.
76. Staskus, K. A., et al. 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71:715-719.
77. Sun, R., et al. 1999. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol. 73:2232-2242.
78. Tang, J., G. M. Gordon, M. G. Muller, M. Dahiya, and K. E. Foreman. 2003. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells. J. Virol. 77:5975-5984.
79. van der Kuyl, A. C., et al. 2005. Cytomegalovirus and human herpesvirus 8 DNA detection in peripheral blood monocytic cells of AIDS patients: correlations with the presence of Kaposi's sarcoma and CMV disease. J. Med. Virol. 76:541-546.
80. Verma, S. C., S. Borah, and E. S. Robertson. 2004. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 78:10348-10359.
81. Wang, C. Y., and B. Sugden. 2004. New viruses shake old paradigms. J. Clin. Invest. 113:21-23.
82. Xiao, B., et al. 2010. Bub1 and CENP-F can contribute to Kaposi's sarcomaassociated herpesvirus genome persistence by targeting LANA to kinetochores. J. Virol. 84:9718-9732.
83. Xu, Y., et al. 2005. A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J. Virol. 79:3479-3487.
84. Xu, Y., A. Rodriguez-Huete, and G. S. Pari. 2006. Evaluation of the lytic origins of replication of Kaposi's sarcoma-associated virus/human herpesvirus 8 in the context of the viral genome. J. Virol. 80:9905-9909.
85. Ye, F. C., et al. 2008. Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-κB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J. Virol. 82:4235-4249.
86. You, J., et al. 2006. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J. Virol. 80:8909-8919.
87. Zhao, J., et al. 2007. K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis. PLoS One 2:e1067.
88. Zhong, W., H. Wang, B. Herndier, and D. Ganem. 1996. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl. Acad. Sci. U. S. A. 93:6641-6646.
89. Zhou, F. C., et al. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J. Virol. 76:6185-6196.
90. Zhu, F. X., X. Li, F. Zhou, S. J. Gao, and Y. Yuan. 2006. Functional characterization of Kaposi's sarcoma-associated herpesvirus ORF45 by bacterial artificial chromosome-based mutagenesis. J. Virol. 80:12187-12196.